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Abstract
Title: EFFECTIVENESS AND MONITORING OFANTIRETROVIRAL THERAPY FOR HIVINFECTED CHILDREN IN ACCRA, GHANA
Authors: Oliver M. Barry, Meghan Prin, Lorna A. Renner, Bamenla Goka, Jonas Kusah, Kwamena W.
Sagoe, and Elijah Paintsil. Section of Infectious Diseases, Department of Pediatrics, Yale University,
School of Medicine, New Haven, CT.

Despite advances in HIV diagnosis and care, many challenges remain in resource-limited settings.
As scale-up of antiretroviral therapy (ART) progresses in resource-limited settings, evaluation of available
first-line regimens and monitoring techniques is needed to ensure the safety and success of such efforts.
This study had two specific aims. First, the study aimed to evaluate the effectiveness of first-line ART
regimens at a large HIV program in Ghana where participants are predominantly infected with non-type B
HIV virus. Second, the study aimed to investigate the potential value of laboratory-based biomarkers,
specifically absolute CD4 cell count, CD4 cell percentage and HIV RNA viral load in predicting failure on
ART. This study enrolled a prospective cohort of 87 HIV-infected children receiving care at Korle Bu
Teaching Hospital in Accra, Ghana. Blood samples were collected a 4-6 month intervals and participants
were followed until treatment failure, defined by WHO criteria, as the primary study outcome. 83% of
participants demonstrated effective treatment response to first-line regimens with 0% associated mortality
and only 4.7% switched regimens over the study period. Predictors of treatment failure included a shorter
time interval between HIV diagnosis and ART initiation (p=0.014) and parents who are both HIV-positive
(p=0.05). Lower mean baseline absolute CD4 cell count appears to be a significantly predictor for
immunological failure (p=0.041). Absolute CD4 cell count and CD4 cell percentage after ART initiation
showed similar trajectories and patterns. The findings demonstrated that available first-line ART regimens
were effective, well tolerated and potentially durable in this setting with little evidence of resistance or
toxicity. In settings in which CD4 cell percentage is not readily available, absolute CD4 cell count may
provide an alternative biomarker for monitoring treatment response. These conclusions hold valuable
public health implications in the scale-up of ART access and monitoring.
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Effectiveness and Monitoring of Antiretroviral Therapy for HIV-Infected Children
in Accra, Ghana

1. INTRODUCTION

A. Advances in HIV management

The development, advancement and utilization of antiretroviral therapy (ART)
has significantly affected the management and outcomes for all people infected with
HIV. The use of ART, particularly combination therapy known as highly active
antiretroviral therapy (HAART), has resulted in tremendous reductions in both morbidity
and mortality for HIV-infected individuals, particularly those living in resource-rich
countries. The rate of perinatal HIV transmission in resource-rich countries has been
reduced by 98-99% following the advent of ART3. In the United States, there were only
67 children in all of 2007 that were born with HIV4. Remarkably, the last child born with
HIV at Yale-New Haven Hospital was delivered in November 19965 and the hospital has
just celebrated this 15 year record of achievement.
Beyond prevention of transmission, the use of ART has improved both the quality
and the quantity of life for people infected with HIV throughout the entire world6. A
particularly notable achievement in the pediatric population has been the positive effect
that ART has brought to nutritional status. In the first year of ART, the average weight
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gain for children is as much as 3.6 kg, which raises the mean weight-for-age z score by
one standard deviation3.
Due to the remarkable advances delivered through the use of ART, a worldwide
effort has been undertaken to create universal access to ART. The scale-up of ART
access in resource-limited settings is increasingly feasible due to a boost in global
funding for HIV/AIDS in the previous decade combined with reduction in drug costs. In
these settings, there has already been a remarkable increase in access. By the end of
2007, an estimated three million people were receiving ART in low and middle-income
countries7, 8. This represents over a seven fold increase in the amount of people receiving
ART in the previous four years8. The increase is likely due in part to innovative models
of delivery, including home-based care delivered by trained local health personnel, which
has demonstrated good health outcomes in rural Uganda9.
The scale-up not only appears feasible, but it has been shown to be highly cost
effective, even in the Africa-specific context6. A study done by Cleary et al. in
Khayelitsha township near Cape Town, South Africa, found that ART is cost-effective at
a cost of $1,300 per quality-adjusted life year (QALY) gained10. This study was
conducted using data from a clinic providing comprehensive HIV care with a cohort of
1,729 adult patients followed for a minimum of four years on ART10. In Cote d’Ivoire,
Goldie et al. also found that ART was highly cost effective, even in the absence of lab
monitoring techniques, and demonstrated that ART was most cost effective when used in
combination with antibacterial prophylaxis11.
The health outcomes for patients receiving ART in resource-limited settings,
Africa in particular, have been encouraging. In the pediatric population overall, ART in
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resource-limited countries has been as effective as ART in resource-rich countries3, 12.
Pediatric specific studies of the effectiveness of ART have been done in South Africa13,
Cote d’Ivoire12, Kenya14, Uganda and Zimbabwe15. At six months, survival on ART was
92% or higher12 and survival at five years on ART was 87% or greater15. A large study
done by Davies et al. in South Africa included outcomes for 20% of all children on ART
in South Africa and demonstrated that mortality at three years on ART was as low as
7.7%13. Of particular relevance to our study, a database of pediatric HIV patients in West
Africa from 2000 through 2008 was analyzed and showed 92% survival after twelve
months of ART16. This study included nine clinical centers in six West Africa countries,
including Ghana.
Furthermore, the children receiving ART in resource-limited settings have
demonstrated low toxicity and similar issues of adherence and retention as in resourcerich settings. For children receiving ART in multiple centers run by Medecins Sans
Frontieres (MSF) throughout Africa and Asia, only 3.8% of patients experienced severe
toxicities17. In a study done in Kenya by Wamalwa et al., 10% of pediatric patients
experienced severe adverse effects necessitating a switch in antiretroviral regimen14, in a
setting in which the majority of patients started on a regimen including two nucleoside
reverse transcriptase inhibitors (NRTI) and one non-nucleoside reverse transcriptase
inhibitor (NNRTI), which is similar to the other African-based pediatric studies.
Adherence to ART in these studies appears good and similar, if not better than, studies in
resource-rich countries. In Uganda, over 97% of patients were found to be taking at least
95% of their pills in any calendar quarter9. Retention of patients in ART programs
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ranged from 73% to 81%, which is similar to studies in adults and in resource-rich
settings13, 16, 17.

B. HIV in Ghana
Ghana, as seen in Figure
1, is located on the West African
coast, bordered by Togo to the
east, Burkina Faso to the north
and northwest, and Cote d’Ivoire
to the west. The population is
estimated at 24.5 million. Life
expectancy at birth is 55 years for
males and 60 years for females.
The maternal mortality ratio is
451 per 100,000 live births. The
infant mortality rate is 50 per 1,000

Figure 1. Map of Ghana and administrative regions
(Source:

live births and the under-five mortality rate is 80 per 1,000 live births1, 2.
The first reported case of HIV in Ghana was in 1986 and a national response to
the disease was organized in 1987. In 2000, the Ghana AIDS Commission was
established to coordinate the management of HIV/AIDS programs nationwide. The
national prevalence of HIV is estimated to be 1.9% in 2009, a decrease from 3.6% in
20032, 18. The highest prevalence is among pregnant women, ages 30-34, where 2% to
4.2% are infected, which illustrates the critical importance of prevention of mother-to-
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child HIV transmission (PMTCT) programs2. There is a marked variation of HIV in
pregnancy by region, as shown in Figure 2, with higher prevalence rates in regions with
larger urban populations.
In Ghana, HIV-1 viral infection is predominant, accounting for 94.4% of
infections and dual infection with HIV-1 and HIV-2 account for 4.4%19. HIV subtype A
and circulating recombinant form (CRF) A/G are dominant in Ghana19.

Figure 2. HIV prevalence rates in Ghana by region (Source: National Guidelines for Prevention of
Mother to Child Transmission of HIV2)

Approximately 267,000 people are living with HIV in Ghana and approximately
9% of those infected are below the age of 15 years2. In 2009 alone, 2,566 children died
from HIV/AIDS in Ghana2. The social effects of HIV on children and families are far
reaching. The Joint UN Programme on HIV/AIDS has estimated that as many as 250,000
children in Ghana have lost at least one parent to HIV18.
As stated above, one area of critical importance in Ghana is PMTCT. In 2009,
3,354 babies were born HIV positive in Ghana and mother-to-child transmission
accounted for 15% of all new cases2. As shown in Figure 3, there are many barriers in
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the PMTCT cascade of management. The first barrier is registration for antenatal
services and PMTCT as needed. Only 53% of all pregnant women even accessed
antenatal services with HIV testing and treatment available. Testing is the second barrier
in the PMTCT cascade for women in Ghana, where only 74% of pregnant women
registered in PMTCT programs were tested for HIV in 2009, which represents only 39%
of all pregnant women in Ghana1. This barrier limits the access of infants to early
diagnosis and prophylaxis treatment. Only 30% of HIV-exposed babies in Ghana
received ART in 20091.

Figure 3. PMTCT statistics in Ghana in 2009 (Source: Prevention of Mother-to-Child Transmission of
HIV in Ghana1)

Despite national and global scale-up of ART, access in Ghana is still a significant
concern. In 2009, approximately 71,000 Ghanaians were in need of ART, but only 14%
of them received it2. Only 7% of those receiving ART were children – a
disproportionately low rate of access given that children represent 9% of all HIV positive
Ghanaians2. One of the factors potentially limiting access to ART is continued

!12!
stigmatization of HIV within communities. In Ghana, 74% of women and 64% of men
would not buy fresh vegetables from a vender with HIV18. Only 21% of children
younger than 15 years have been informed about their disease by their parent or guardian,
which illustrates the lack of communication and persistent stigma surrounding HIV in
Ghana20.

C. On-going HIV epidemic

Despite advances in treatment and access to testing and ART, mother-to-child
HIV transmission continues to raise the pediatric incidence of HIV in developing
countries. Worldwide, there are 1,200 new HIV infections in children less than 15 years
old every day21. 90% of these pediatric infections occur in developing countries and
more than 90% are due to mother-to-child transmission21. Although dramatic increases
in the number of patients receiving ART have been documented, the majority of children
in need are still not receiving therapy. As stated above, in Ghana, only 14% of those in
need received ART in 20092. Globally, children represent only 6.6% of the three million
people receiving ART17. Achieving universal coverage will be a major public health
challenge, particularly in sub-Saharan African countries with high prevalence. For
example, in South Africa alone, it is estimated that more than six million people will
require ART in the next ten years10.
One major factor affecting both prevention of HIV transmission, in the antenatal
population, and mortality, in the pediatric population, is early diagnosis. Only 15% of
HIV-exposed infants receive a diagnostic test within the first two months of life21. This
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lack of early diagnosis translates to significant consequences in child mortality. Onethird of infants die before 1 year, half will die before 2 years and three-quarters of
children succumb before age 5 without treatment17, 21. Subsequently, the age at ART
initiation in resource-limited settings is high, underlining the limited access and coverage
of testing and treatment services. In a large West African cohort, the mean age at ART
initiation was 4.9 years21 and in Ghana, the median age is 5.5 years22. Delayed ART
initiation can be associated with advanced clinical stage and level of immune suppression
at initiation22 and has effects both on the short-term and long-term health outcomes. In
children of all ages, it has been demonstrated that lower CD4 counts at initiation are
associated with impaired recovery and T-cell reconstitution23, which prolongs the period
of vulnerability to opportunistic infections24. In the long-term, children who initiate ART
at an older age had lower age-adjusted CD4 counts after a five year follow-up period,
which indicates that the younger, immature immune system’s ability to recover from HIV
infection may decrease with age and duration of infection, further emphasizing the
critical need for early diagnosis and treatment23.
Many challenges and barriers to universal access and care remain in resourcelimited settings. First, inefficient or non-existent healthcare infrastructure challenges
access and delivery of care. Lack of record keeping and medical documentation is a
infrastructure issue noted frequently in resource-limited settings and is a major barrier3.
At a large treatment center in Cote d’Ivoire, patients experienced involuntary ART
interruptions because of stock exhaustion of ART drugs at the central administrative
level, exemplifying the challenges of infrastructure in HIV care12.
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A second barrier is the limited range and availability of ART formulations. As in
the Cote d’Ivoire example, ART may not always be available but even when available the
different formulations may be sub-optimal. First-line regimens in resource-rich countries
are protease inhibitor (PI)-based therapies25, as a consequence of research demonstrating
reduction in overall mortality versus other combinations14, 26. However, in resourcelimited settings, NNRTI-based formulations remain the most common due to the low
availability and high cost of PI-based regimens.
Third, there are limited numbers of trained healthcare professionals, particularly
physicians. The lack of trained providers, in large part due to “brain drain”, compounds
the issue of inefficient healthcare infrastructure and access to care. Finally, there is only
limited funding available to support activities, particularly in settings with many
competing public health priorities10. This can lead to a challenging ethical and practical
situation where funds could be used either to treat fewer patients more comprehensively
or to use the funds to provide more patients with fewer services10. Furthermore,
significant and associated health issues persist even with access to ART. Pre-existing
malnutrition or immune suppression still leads to significant morbidity and mortality in
the short- and long-term27. Immune reconstitution inflammatory syndrome is a
significant cause of mortality in the first three to six months of ART, and resistance and
non-compliance continue to be major long-term issues27.

D. Monitoring HIV in children
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As the scale-up of ART advances in the developing world, one area that needs to
be addressed is the monitoring of treatment and disease progression. ART is currently a
life-long treatment with potentially toxic adverse effects and vulnerability to the
development of virus resistance. However, current antiretroviral regimens have led to
dramatic reductions in toxicity due to the development of new drug classes and in viral
resistance due to the use of combination therapies. ART remains a long-term therapy
and therefore a feasible and cost-effective monitoring strategy for resource-limited
settings is an important and high priority, and a topic receiving an increasing focus7. If
context-appropriate strategies and technologies are not developed, the success of ART
scale-up could be jeopardized because of the critical current shortage of laboratories with
the technical ability to perform monitoring tests, such as CD4 count and viral load28.
In Africa, ART is often monitored without any routine laboratory monitoring,
which is limited by healthcare infrastructure and cost. The state of healthcare
infrastructures and the current costs of laboratory techniques has led some researchers to
theorize that universal access to ART can only be achieved if done without routine
monitoring29. However, research has demonstrated both the added benefit of monitoring
on patient outcomes as well as the cost-effectiveness of lab-based monitoring techniques,
particularly CD4 monitoring. The DART Trial in Uganda and Zimbabwe showed that
routine CD4 monitoring is superior to clinically driven monitoring with a significant
decrease in disease progression and mortality for patients receiving lab testing on a
routine basis15. This study further found that routine CD4 cell count monitoring lead to
significant decreases in disease progression and mortality compared to a group receiving
ART without routine monitoring15.
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Currently, there are dichotomous standards of pediatric HIV care based on the
patient care setting. For patients in developed, resource-rich settings, ART is initiated at
higher CD4 counts and routine, frequent monitoring is undertaken. The U.S. Department
of Health and Human Services advises the initiation of ART at CD4 cell counts less than
500 or for patients with symptomatic disease and CD4 cell counts above 50030.
Monitoring, including CD4 cell count, CD4 cell percentage and HIV viral load, is
recommended every three months30. In the U.K., similar resource-intense regimens are
recommended including the use of viral load testing at ART initiation, 2-8 weeks after
initiation and then every 3-4 months thereafter7. In fact, these resource-intense
monitoring strategies have been found to be relatively cost-effective at a cost of $3,956
per QALY gained30. However, at the described level of cost, these strategies would no
longer be cost-effective in a low-income country.
The monitoring of ART in resource-limited settings is a distinctively different
strategy. As set forth by the World Health Organization (WHO), ART is initiated for
children less than five years old at a CD4 cell percentage less than 25%, and a CD4 cell
count less than 350 for children five years and older31. CD4 monitoring is recommended
every six months and viral load testing is not part of the WHO guidelines31. Increased
frequency of CD4 testing, the use of viral load and resistance testing, all represent
additional system costs that may not be realistic with limited resources, current
technologies and lack of healthcare infrastructure3. The difference in strategies and
recommendations illustrates the need for research focus on this topic, particularly in light
of the demonstrated benefits with routine laboratory-based monitoring. As more children
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are treated with ART, the monitoring strategy and practice must be evaluated and
optimized for best patient outcomes.
The most important parameter for monitoring HIV progression and ART has been
the CD4+ T lymphocyte cell count. The use of CD4 cell counts provides a quantitative
guideline for treatment initiation prior to the development of clinical symptoms, which
has been proven to reduce morbidity and mortality32. As a screening tool for ART
initiation, CD4 cell counts are significantly more specific than clinical criteria, which
would fail to identify up to 70% of eligible patients without CD4 testing6. Studies in
South Africa and Cote d’Ivoire strongly support the use of CD4 cell counts as a relatively
low-cost technique to guide ART initiation in ART scale-up programs6.
As a monitoring tool for ART and HIV disease progression, CD4 cell counts have
enhanced the benefits of ART and have done so in a cost-effective way. In a study done
in Cote d’Ivoire, the use of routine CD4 cell count monitoring increased life expectancy
for patients at least one full year11. Kahn et al. found that in Uganda the use of CD4 cell
count monitoring is even more cost-effective than ART alone, and particularly more cost
effective than the addition of viral load testing9. The WHO, in its guidelines, recognizes
the value and the limited access to CD4 testing, recommending that in areas with limited
access to CD4 testing, the use of these resources should be targeted based on clinical
events21.
In the management of pediatric HIV, monitoring CD4+ T-lymphocyte counts is
done using both CD4 cell count and CD4 cell percentage. In all children, CD4+ Tlymphocyte counts are very high during early childhood and physiologically decline as
the child ages and immune system develops, stabilizing at similar levels as adults after
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five years of age33, 34. Furthermore, wide variations in CD4 cell count between and
within individuals has been demonstrated35. Therefore, due to the variation of CD4 cell
count between both individuals and age groups, CD4 cell percentage has been used as a
potentially optimal biomarker. The CD4 cell percentage may remain stable across age
groups and individuals and could be used as a parameter for the initiation of ART and
monitoring of treatment in children24.
While CD4 cell percentages were previously the recommended parameters for all
pediatric age groups, the guidelines are now shifting both in the U.S. and internationally,
towards increased use of absolute CD4 cell counts. Research has shown that CD4 cell
counts normalize to adult values at approximately six years old and the CD4 cell count
thresholds used in adults have similar prognostic value in children and adolescents36-38.
The WHO now recommends the use of absolute CD4 cell counts for all children from
five years and older31.
Additionally, there is growing research in the U.S. and Europe that suggests
absolute CD4 cell counts could be reliable alternatives to CD4 cell percentage. There can
be significant discordance between CD4 cell count and cell percentage when used as a
screening tool for pediatric ART initiation. As many as 50% of all pediatric patients
eligible for ART by at least one CD4-based criteria (either absolute cell count or
percentage) have discordant values39. However, statistical models suggest that the CD4
cell percentage had no significant prognostic value over and above that of absolute CD4
cell count, irrespective of age39. In a New Haven pediatric HIV cohort, Paintsil et al.
recently demonstrated that the absolute CD4 cell count is as reliable as using CD4 cell
percentage in the monitoring of disease progression, regardless of the ART regimen40.
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This cohort included 97 participants and was followed over a ten-year period but had
small numbers in the 0-5 year age group, limiting the power of the study to report on
differences in younger age groups.
Viral load testing is another parameter used in the monitoring of HIV disease
progression. Landesman and Burns postulated the value of viral load monitoring in
199641 and their ideas have been confirmed in subsequent research. First, viral load is
perhaps the most valuable indicator of response to treatment42. CD4 cell counts shortly
after ART initiation do not reflect the HIV viral burden and therefore viral load testing is
a more sensitive biomarker to detect virological failure7, 42. Therefore, as an early
indicator of treatment effectiveness, viral load testing can be used to guide changes in
treatment regimen. WHO recommends the use of viral load testing prior to change in
treatment regimen31 and regimen switching based on viral load testing leads to earlier
switching and increased life expectancy as compared to regimen switch based on CD4
counts alone8, 30. CD4 counts may take months to start declining to levels meeting
immunological failure criteria after virological failure3, which additionally increases the
potential accumulation of resistance mutations29. The second demonstrated value of viral
load testing is as an indicator of disease progression. Baseline viral load levels are
independently associated with overall mortality43 and changes in viral load are predictive
of progression to AIDS42 and other significant clinical events27. These findings have
been confirmed in the African context by Obimbo et al in a study evaluating viral load
burden and infant mortality44.
Despite the certain value of viral load testing, there are limitations to its use,
particularly in the resource-limited setting. First, children exhibit different viral load
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responses to treatment in comparison to adults. Asymptomatic children are less likely to
achieve viral suppression as compared to adults and may even have high viral loads that
fluctuate or remain high in spite of strong adherence and CD4 count recovery40.
Additionally, the decline in CD4 cell counts may not correlate with the viral load levels, a
finding reported by Rodriguez et al40. Finally, the high cost of viral load testing makes its
routine use in a resource-limited setting widely prohibitive. As a screening tool for ART
initiation, viral load testing would cost $1700 per person identified in addition to the cost
of CD4 testing45. As a tool for routine disease monitoring, viral load testing would have
approximately ten times the cost per disability-adjusted life year (DALY) compared to
schemes of clinical monitoring plus CD4 testing9.
Due to the limitations of both CD4 testing and viral load testing, alternative
biomarkers have been studied. In particular, total lymphocyte count (TLC) has been
evaluated for use as an alternative to CD4 testing in resource-limited settings. TLC
testing is low cost, utilizes an automated hematology analyzer and therefore requires
minimal technical expertise, and has been proposed as an alternative to CD4 testing until
those techniques are more widely available46, 47. In resource-limited settings of South
Africa and in the U.S., TLC has been found to be positively correlated with absolute CD4
count and an independent predictor of mortality48-50. However, in a meta-analysis, there
was a weak correlation between TLC and CD4 cell percentage46. Based on the
demonstrated value of CD4 testing, both absolute cell count and cell percentage, as lowcost methods are further developed and widely accessed, alternative biomarkers such as
TLC will not be necessary.
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E. Technological advances

As access to ART scales up with the goal of universal access, low cost methods of
monitoring treatment effectiveness and disease progression are a priority in resourcelimited settings. Development of CD4 technologies is on the forefront of the advances.
The major factors limiting widespread use of CD4 testing done by conventional flow
cytometry are cost and technical expertise6. Flow cytometry techniques and instruments
require technical expertise to prepare and process specimens, are associated with high
cost of equipment and maintenance as well28, 51.
New, non-flow cytometry based techniques, are rapidly being developed. Two
promising technologies are Dynabeads® by Invitrogen, and the Daktari CD4 by Daktari
Diagnostics, Inc. Dynabeads® is a cell separation technology using magnetized spherical
beads52. This technology has been in use for various cancer research and is associated
with a lower cost compared to current flow cytometry-based methods51. The feasibility,
cost and accuracy of the Dynabeads® technology was evaluated in studies including five
West African countries – Burkina Faso, Cote d’Ivoire, Senegal, Togo and Mali. This
study by Diagbouga et al. found that the Dynabeads ® techniques were strongly
correlated with the results of flow cytometry from the same samples and at a significantly
lower cost than flow cytometry techniques51. The Dynabeads ® techniques were easily
implemented at the six different research sites and cost $3 per assay, compared with the
$25 per assay for flow cytometry51.
The Daktari CD4 instrument is a portable, point-of-care CD4 assay that utilizes
two non-flow cytometry techniques – microfluidic cell chromatography and lysate
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impedance spectroscopy53. Microfluidic cell chromatography is a rapid cell separation
technique shown to have high efficiency and purity54. Lysate impedance spectroscopy is
a cell counting, non-optical, technique using measured changes in intra- and extracellular
electrical conductivity55. This instrument is currently being further studied to evaluate
accuracy and performance but would potentially provide a low-cost and highly mobile
point-of-care system, adaptable and appropriate for far-reaching ART distribution
programs.
Despite the advances and innovation, these new technologies, and others like
them, do not have the capacity to compute CD4 cell percentage40. This limitation is
especially relevant in the pediatric HIV population in which CD4 cell percentage is the
recommended biomarker for monitoring for children less than five years old. Therefore,
the pediatric HIV community currently, without further research in use of absolute CD4
cell count, is not poised to take advantage of these technologies when they do become
widely available.
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2. SPECIFIC HYPOTHESES AND AIMS

This study had two specific aims. The first specific aim (1) was to evaluate the
effectiveness of first-line ART regimens at a large pediatric HIV program in Ghana. It
was our hypothesis that first-line ART regimens at Korle Bu Teaching Hospital in Accra
would be highly effective in this resource-limited setting of non-type B HIV-1 infection.
The second specific aim (2) was to evaluate the prognostic value in laboratorybased biomarkers, specifically absolute CD4 cell count, CD4 cell percentage and HIV
RNA viral load in predicting treatment failure on ART. It was our hypothesis that
absolute CD4 cell count can be used as an alternate and equivalent biomarker to CD4 cell
percentage in a resource-limited setting and in children of all ages, for the monitoring and
evaluation of treatment response and HIV disease progression.
The specific aims of the study have two significant public health implications.
The first public health implication is regarding the choice and array of available
antiretroviral treatments in Ghana. Currently, the selection of available antiretroviral
regimens is based on historical research conducted in resource-rich settings with different
HIV subtypes, and limited in Ghana by cost. By evaluating the current ART regimens in
Ghana and their effectiveness, this research can offer critical comparative analyses on the
existing regimens for naïve patients and make meaningful suggestions regarding the
development of effective yet affordable regimens in order to avoid drug resistance.
Resistance to currently available regimens for treatment-naïve patients would have
potentially disastrous consequences as ART scale-up progresses. Additionally, based on
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the effectiveness data, this research could suggest the vital need for greater production of
the component parts of current regimens, promoting increased generic manufacture of
current regimens and thereby boosting access to treatment.
The second public health implication of this project is to demonstrate the value of
absolute CD4 count in a resource-limited setting in order to promote its acceptance and
use in pediatric populations. Consequently, emerging point-of-care absolute CD4
technology could be made available for use and study in pediatric HIV populations. The
use of these technologies would have the potential to increase access to ART initiation in
rural, difficult to reach communities and enhance the ability to monitor ART in children,
thereby reducing toxicity and drug resistance.
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3. METHODS

This study was a two-year project with specific aims as listed in the previous
section. The study was reviewed and approved by the Ethics and Protocol Review
Committees of the University of Ghana Medical School and the Human Investigation
Committee of Yale School of Medicine.
The study was conducted in three parts. The first part of the study (1) involved
the enrollment of study participants, which included recruitment, consent and initial
interviews. The second part (2) was the prospective collection of data at follow-up clinic
visits. The third part of the study (3) was the statistical analysis of the data collected.

A. Enrollment

The study was conducted at the Korle Bu Teaching Hospital (KBTH) in Accra,
Ghana, which is the largest hospital facility in Ghana and the third largest in all the West
Africa region56. The hospital, as a whole, has approximately 2,000 inpatient beds, is the
primary teaching hospital for University of Ghana Medical School, and is the primary
referral center for at least the Greater Accra and Eastern regions of Ghana. However,
patients in reality traveled to KBTH from all over the country and West Africa region.
The Department of Child Health at KBTH was the main site for this study. The
Child Health Department at KBTH provides the highest level of pediatric care in the
nation and has an impressive volume of cases, including the following annual statistics56.
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There are 11,000 inpatient admissions reported annually including 2,000 neonatal
intensive care admissions. Additionally, there are 36,000 outpatients visits reported and
10,500 patients are being followed routinely at sub-specialty clinics at the Department of
Child Health.
This study recruited and enrolled a prospective cohort comprised of HIV-infected
children receiving care at KBTH. All children received care through the Pediatric
HIV/AIDS Care program at KBTH. This program was established in 2004 and provides
comprehensive HIV/AIDS care and management of opportunistic infections for HIVinfected children. The pediatric HIV clinic is operates on a weekly basis and patients are
referred to this clinic through one of several channels. To be referred, children either:
have mothers known to be HIV-positive during pregnancy and were participating in the
program for prevention of mother-to-child transmission (PMTCT); are discovered to be
infected after presenting with an AIDS-defining illness; or are diagnosed after a
symptomatic sibling or parent was found to be HIV-positive. The majority of HIVpositive children are infected in the perinatal period and the Pediatric HIV/AIDS Care
program now cares for over 1,100 children including those with a confirmed diagnosis as
well as HIV-exposed infants who are pending final status determination.
Potential participants were identified through collaborative efforts between
research assistants, physicians, pharmacists and counselors. The inclusion criteria were
age between 0 and 12 years, confirmed HIV infection and naïve to ART. Children were
defined as having a confirmed HIV infection if rapid serum antigen and antibody testing
were positive after 18 months or they had two detectable HIV RNA levels using PCR
after delivery as per WHO guidelines57.
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All participants received written and verbal information about the study and gave
consent before enrollment along with assent from parents or guardians. These
discussions took place in a private and confidential space at the Department of Child
Health. A written consent form was developed in English. If the participant or guardian
did not speak English, a translator was available and would assist in explaining the details
of the consent. If participants or their guardians were unable to write, they provided their
fingerprint with ink, as is a common practice for illiterate individuals in Ghana, in lieu of
a written signature, to indicate their consent. All participants received a copy of the
consent form after signing.
After giving written consent, participants were enrolled in this study and were
given a unique number and no identifying information was kept with study data.
Enrollment began in September 2009 and continued through May 2011. At the time of
enrollment, participants and guardians were interviewed to document demographic and
background information including HIV diagnosis date, mode of transmission (if known),
ARV start date, ARV regimen, parental status (if known), parental HIV status (if known),
participant’s tuberculosis (TB) status and history, past PMTCT treatment for mother,
status and HIV status of participant’s siblings (if known) and the participant’s disclosure
status (whether the child knows his/her diagnosis). As at any time during the study, if the
participant or guardian did not speak English, a translator was provided. Pediatric
HIV/AIDS Care Program files as well as hospital files were reviewed at the enrollment
interview. These medical records were reviewed to validate background information
verbally reported to research assistants as well as to collect clinical data preceding
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enrollment such as prior WHO staging, previous CD4+ T-lymphocyte testing, previous
HIV viral load testing and growth data (weight and height).

B. Data collection

The second part of the study was the prospective data collection after enrollment
and ART initiation. The first study visit and data collection was near the time of
enrollment. Blood samples were obtained for CD4 absolute cell count and cell
percentage, HIV viral load and complete blood count. The first data point was within
three months, either before or after, ART initiation. If tests, such as CD4 testing, had
already been performed at the time of enrollment and within three months of ART
initiation, these tests were not repeated and the preceding data was collected.
After enrollment and the initial study visit, participants were seen and examined
at the pediatric HIV clinic at least every 4-6 months and more frequently as necessary.
At each visit, the participant’s weight and height were measured and the patient’s WHO
staging was updated. Every 4-6 months during the study period, blood samples were
collected and CD4 absolute cell count and cell percentage, HIV viral load, and complete
blood count were tested. Additionally, participants and guardians were interviewed at
each follow-up visit to assess adherence to therapy. Adherence was measured in several
methods. First, participants and guardians were asked to self-report the number of doses
missed by the participant in the previous three days. Second, dates and timing of
pharmacy refills were cross-checked if adherence was questioned. Additionally, missed
clinic appointments were also documented for use as a potential marker of participant
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adherence. Medical records were also reviewed at follow-up visits to recognize and
document interim hospitalizations and unscheduled clinic visits to identify opportunistic
infections.
All blood samples were processed at laboratories at KBTH. CD4 absolute cell
count and cell percentage were quantified by a dual-platform flow cytometry technology
using a FACSCount system (Becton-Dickinson, Franklin Lakes, NJ, USA) at the clinical
laboratory at the Fevers Unit at KBTH according to manufacturer’s instructions.
Samples were processed within four hours and results were delivered on the day
following delivery. The laboratory is certified by the South African Public Health
Reference Laboratory and participates in an external quality assurance testing program by
the South African Public Health Reference Laboratory. The HIV RNA viral load testing
was performed at the Virology Lab at KBTH. In this lab, the COBAS ® AMPLICOR
Monitor test (Roche Diagnostic Systems, Branchburg, NJ, USA) was used for the
quantification of the HIV-1 RNA with a detection limit of 400 copies/mL. The testing
was performed according to the manufacturer’s instructions. Starting in September 2011,
some viral load testing was performed at the Central Laboratory at KBTH after viral load
instrument were procured. At this laboratory, the COBAS ® TaqMan ® 48 Analyzer
(Roche Diagnostic Systems, Indianapolis, IN, USA) was used with a detection limit of 20
copies/mL. When processing blood samples for all viral load testing, an additional
plasma sample was set aside and put in frozen storage for potential future use in
resistance testing and other research.

C. Statistical analysis
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The statistical analysis for this study was undertaken in accordance to the specific
aims of the study.

i. Effectiveness of first-line ART regimens

The primary outcome of the study was treatment failure, either virological or
immunological failure. The criteria used for treatment failure was the criteria set forth by
the WHO31:
•

Virological failure was defined as a viral load > 5,000 copies/mL after at
least 24 weeks on ART.

•

Immunological failure was defined based on age. For children between 2
and 5 years, immunological failure was defined as absolute CD4+ Tlymphocyte count persistently < 200 cells/microliter or CD4+ Tlymphocyte percentage < 10 % after at least 24 weeks. For children 5
years and older, immunological failure was defined as absolute CD4+ Tlymphocyte count persistently < 100 cells/microliter after at least 24
weeks.

After identification of potential treatment failures, based on laboratory results
using the criteria above, particularly those with viral load greater than 5,000 copies/ml
after 24 weeks on ART, participants were seen in the clinic sooner than the standard 4-6
month follow-up period. The purpose of the clinic visit was for a clinical assessment and
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full interview by the team of physicians to assess the level of medication compliance.
The participant’s medical records were scrutinized, particularly the pharmacy refill
schedule, and the participant and guardian were counseled about the importance of
adherence to the ART regimen. Repeat blood samples were then collected at the next
clinic visit, which was scheduled 4-6 months after the previous sample collection. Based
on the two follow-up visits and repeat laboratory measurements, the participants were
determined to be either treatment failures or non-compliant. For participants failing
treatment, physicians made subsequent decisions to change ART regimens. These
participants had reached the primary outcome of this study and were no longer followed.
For participants deemed non-compliance, further counseling was conducted and the
participant remained on the first-line regimen. These participants continued to be
followed in this study.
To determine associations between baseline characteristics, statistical analyses
were performed using SAS (SAS Institute, Cary, NC, USA). Participants were excluded
from analysis if they did not have a data point 24 weeks or later after ART initiation. For
baseline demographic characteristics, Chi-square and Fisher’s exact tests were used. For
baseline laboratory variables, Wilcoxon Rank-sum tests were performed. To analyze
agreement between immunological and virological failures, a 2x2 table was produced and
the kappa statistic was calculated.

ii. Use of absolute CD4 cell count
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To analyze individual short-term responses to ART based on absolute CD4 cell
count, CD4 cell percentage and viral load, spaghetti plots were constructed using baseline
data points and subsequent data points up to 30 weeks following ART initiation. To
analyze the use of absolute CD4 cell count as an alternative to CD4 cell percentage,
graphs depicting the trends and trajectories of absolute CD4 cell counts and CD4 cell
percentages over a 24-month follow-up period were produced. These graphs were used
to identify trends in the data and descriptively analyze any similarities or differences.
Data points from participant laboratory values were grouped according to timing relative
to ART initiation and designated to a clinic visit number representing 6-month intervals
(i.e., visit 1 represents baseline, visit 2 represents 6 months after ART initiation, visit 3
represents 12 months, etc.). Data were designated to clinic visit number if the data was
collected in a 3-month interval surrounding the visit number.

D. Author responsibilities

I was the second Doris Duke Clinical Research Fellow involved in this two-year
project. As such, I was specifically and personally responsible for:

•

Adjustments and improvements to the study protocol

I was personally responsible for the identification and definition of specific
inclusion criteria for this project, in particular the timing between enrollment and initial
data collection and the enrollment of only ART-naïve patients.
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•

Enrollment of study participants in the second year of the study

I identified, recruited and enrolled participants in this study from September 2010
through May 2011. During this time period, I enrolled 33 participants. I conducted the
initial interviews at enrollment and with the assistance of Mr. Jonas Kusah, our research
assistant and translator, as needed. I was also responsible for the review of the
participant’s clinic file, hospital file and all laboratory results at this initial visit.

•

Tracking of study visits and collection of study samples

I developed computer-based systems for tracking the visits and sample collections
of all enrolled participants so as to minimize lost-to-follow up and inappropriate time
intervals between participant sample collections. I was responsible for the tracking of 91
enrolled participants and collection of study samples at appropriate time intervals.
During my time in Ghana, I coordinated 174 study visits for enrolled participants in
which study samples were collected. At all study visits, I conducted the interviews to
monitor ART adherence, reviewed the patient’s medical records to identify interim
hospitalizations, opportunistic infections and missed appointments. I delivered blood
samples to the various appropriate laboratories, collected the results and inputted all data
into our project database.
Mr. Sampson Bonney at the Child Health Laboratory collected the blood samples.
The CD4 testing was conducted in the Fevers Unit by lab technicians. Mr. Isaac Kofi
Badu, Mrs. Makafui Seshie and Mr. Isaac Boamah conducted the viral load testing in the
Virology Lab with supervision by Dr. Kwamena Sagoe.
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Furthermore, while I was in Ghana, the physicians working in the HIV clinic
expressed strong interest in the immediate clinical use of our longitudinal study data.
Thereafter, I established a computer-based, secure and sustainable system for the study
data to be available to all clinic physicians on a real-time basis thereby maximizing the
clinical relevance of the research study data.

•

Preliminary data analysis

I performed the preliminary data analysis near the end of my fellowship in Ghana.
The analysis was an integral part of a presentation I made to the Department of Child
Health staff in May 2011. This data analysis was also used in several abstract
preparations and poster presentations at Yale Student Research Day and the Doris Duke
Clinical Research Fellowship Conference, both in May 2011. Further and final data
analysis was led by Veronika Northrup and Karol Katz from the Yale Center for
Analytical Sciences though I had an active role in the preparation of the data and did
directly undertake several of the statistical analyses.

•

Identifying and assisting future collaborations

I acted to identify and assist future collaborations between KBTH (University of
Ghana Medical School) and Yale School of Medicine, particularly in the study of
virological failure and resistance patterns. I assisted with the storage of extra study
samples to be used in the future to study the development of HIV resistance patterns in
this longitudinal cohort at KBTH. Additional samples were collected for all participants
identified as treatment failures and additional samples were stored. During my work

!35!
period in Accra, several samples were processed and evaluated for resistance, and a
collaboration was established for future study with continued support from the Doris
Duke Clinical Research Fellowship program.

•

Day-to-day team leadership and study implementation

While in Ghana, I was in charge of the day-to-day implementation of the study
protocol and the management and protection of all study data. These responsibilities
included cooperation with all study personnel, coordination of team meetings and
procurement of laboratory supplies.
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4. RESULTS

A. Study Participants

There were 96 clinic patients initially recruited for enrollment into this study, as
shown in Figure 4. Nine patients were subsequently excluded from enrollment and
inclusion in the study. One child was identified several weeks after initial recruitment to
be starting a second-line ART regimen and was therefore excluded. Sadly, this patient
died several months after starting the second-line regimen, likely due to an abdominal
lymphoma. One child upon further laboratory investigation was found to be HIVnegative and thereafter excluded from the study. Seven patients were recruited in the
first year of the study before ART initiation. Study personnel continued following these
patients to monitor the timing of ART initiation. However, by the end of data collection
for this project, the seven children were still not yet on ART and were thereby excluded.
Eighty-seven participants were enrolled into the study and at the time data
collection was closed for the purposes of this study, 63 participants had a complete data
set that included baseline laboratory values and follow-up laboratory values at least 24
weeks after ART initiation. At least 24 weeks of follow-up data was needed in order to
evaluate the effectiveness of ART based on WHO criteria. These 63 participants were
included in the full data analysis and therefore are the participants described in Table 1.
Twenty-four of the enrolled participants were excluded from the data analysis due to
missing data. Data was missing for these participants due to several challenges. Some
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initial blood samples were not collected in the designated window surrounding ART
initiation, which was +/- three months before or after ART initiation. Additionally, some
blood samples were affected by technical difficulties in specimen processing. A small
number of samples were misplaced in the processing and mistakes were not discovered
until after the baseline window had past. Other participants had not been enrolled for at
least 24 weeks and therefore follow-up sample collection was not yet possible. For these
enrolled participants who were awaiting collection of follow-up data, samples will be
collected at the appropriate time for further research purposes related to a broader
research context.

96
participants
recruited

87
participants
enrolled

9 participants
excluded

1 on 2nd line
ART regimen
(mortality)

1 HIVnegative

7 not yet
started on ART

63
participants
with complete
data

24
participants
with missing
data

Figure 4. Enrollment flow chart

Table 1 illustrates the demographic characteristics of the study population (n =
63). There were slightly more male participants than female (57.1% versus 42.9%), and
the mean age of all participants at ART initiation was 6.4 years (SD = 3.1). The youngest
participant included in this data analysis was 1.2 years at the time of ART initiation and
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the oldest was 12.8 years. The mean number of days between HIV diagnosis and ART
initiation was 294 days (SD = 494), representing a period of approximately 10 months
from the time that a child was found to be HIV-positive and when he/she started ART.
At the time of the initial interview, the participants or guardians were asked to
report who the primary caregiver for the child was. For forty participants (63.5%), the
primary caregiver was a parent, either the child’s mother or father. However, for 36.5%
of the participants the primary caregiver was someone other than a parent. The “other”
caregivers included grandmother, aunt, uncle, an older sibling or a friend of a parent.
The various modes, and suspected modes, of HIV transmission are displayed in
the table. A mode of “maternal” transmission was determined when the mother of the
participant was known to be HIV-positive. In our study, this was the majority of the
cases, with 69.8% of all participants having an HIV-positive mother. The mode of
transmission was deemed “suspected maternal” when the mother’s HIV status was
unknown due to lack of testing or the mother was deceased. In these cases, due to the
published research on the overwhelming majority of new pediatric HIV cases being
caused by maternal transmission, it was decided to deem these cases “suspected
maternal”. The mode of transmission was deemed “unknown” in cases in which the
mother’s status was known to be HIV-negative. There were four such cases (7.9%) in
our study population.
Participants and guardians were asked about PMTCT services received by mother
and child during and after delivery. Only one participant (1.6%) had documentation
showing receipt of PMTCT services for mother and child during and after delivery. The
majority of participants (88.9%) reported no PMTCT services received by mother or
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child and 9.5% of the participants did not know whether PMTCT services were received.
Most of the cases in which PMTCT services were unknown were in cases of deceased
mothers where a guardian who did not know the full details of the child’s birth history
was caring for the child.
A significant proportion of the study participants was orphaned, presumably due
in large part to HIV/AIDS. 42.8% of participants had lost one or both of their parents at
the time of enrollment. As expected, the majority of participants had at least one parent
with known HIV infection (74.6%). The rest of the participants did not know the status
of either one of their parents. While the rates amongst participants’ parents were
expectedly high, the prevalence of HIV among participants’ siblings was low. Only four
participants (6.3%) had siblings with known HIV infection. More than one-quarter
(27.0%) knew that all siblings were HIV-negative and 27.0% had no siblings.
The low levels of disclosure reflect both the young average age of the study
participants and the social stigma still surrounding the diagnosis of HIV. Partial
disclosure was defined as the child knowing that he/she was sick and receiving treatment,
but did not know the illness was HIV. Complete disclosure was defined as knowledge of
illness and HIV. Few participants in our study even knew they were sick. 90.5% had no
knowledge of their illness or HIV.
The predominant ART regimen consisted of two nucleoside reverse transcriptase
inhibitors (NRTI) and one non-nucleoside reverse transcriptase inhibitor (NNRTI). The
most popular regimen used (79.4%) was lamivudine (an NRTI, abbreviated 3TC),
zidovudine (an NRTI, abbreviated AZT) and efavirenz (an NNRTI, abbreviated EFV). In
17.4% of cases, nevirapine (an NNRTI, abbreviated NVP) was substituted for EFV. One
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patient was on a regimen of 3TC, AZT and abacavir (an NRTI, abbreviated ABC) while
the remaining patient was taking 3TC, EFV and ABC. The use of ABC was mainly due
to interactions with anti-TB medications.
The WHO utilizes a system to stage the severity of HIV disease based on clinical
findings and evidence of various opportunistic infections. Stage I is deemed
asymptomatic disease, stage II is mild disease, stage III is advanced and stage IV is
severe. ART initiation is recommended at stages III and IV regardless of laboratory
results. Therefore it was not unexpected that the large majority of our participants
(79.5%) were in stage III or IV at the time of ART initiation.
One concomitant infection for which we screened through the interview and chart
review was TB. At the time of ART initiation, 39.7% were previously or currently
infected with TB. Throughout the follow-up period, we monitored and documented any
new diagnoses of TB and used this variable in the data analysis to evaluate any effect that
this common concomitant infection may have on the effectiveness of ART in our study
population.
Height and weight were recorded at every clinic visit. Z scores were generated
and demonstrate the number of standard deviations away from the mean for age-adjusted
worldwide population. A significant proportion of our participants were below two
standard deviations from the mean in height (38.0%) and weight (47.3%). Body mass
index (BMI) was calculated using the height and weight of participants. The mean BMI
for all participants was 14.8.
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Table 1. Baseline Demographic Characteristics (n = 63)
Characteristic

Participants (%)

Gender
Female

27 (42.9)

Male

36 (57.1)

Age at ART initiation
0 – 2 years

6 (9.5)

2 – 5 years

18 (28.6)

≥ 5 years

39 (61.9)

Primary caregiver
Parent (mother / father)

40 (63.5)

Other (grandparent, other relative)

23 (36.5)

Mode of HIV transmission (n = 62)
Maternal

44 (69.8)

Suspected maternal

14 (22.2)

Unknown

4 (7.9)

PMTCT treatment received
Yes

1 (1.6)

No

56 (88.9)

Unknown

6 (9.5)

Parental living status
Known both alive

36 (57.1)
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Known one alive
Both died or unknown

21 (33.3)
6 (9.5)

Parental HIV status
Both parents with HIV

16 (25.4)

One parent known with HIV

31 (51.7)

Both parents unknown

16 (25.4)

Siblings with known HIV
Yes

4 (6.3)

No

17 (27.0)

Unknown

25 (39.7)

No siblings

17 (27.0)

Disclosure to patient (n = 60)
None

57 (90.5)

Partial

2 (3.2)

Complete

1 (1.6)

ART regimen
Lamivudine, zidovudine, efavirenz

50 (79.4)

Lamivudine, zidovudine, nevirapine

11 (17.4)

Other

2 (3.2)

WHO stage at ARV initiation (n = 59)
I

3 (5.1)

II

15 (25.4)

III

24 (40.7)
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IV

17 (38.8)

Previous TB infection
Yes

25 (39.7)

No

38 (60.3)

Height z score (n = 41)
-2 or below

10 (38.0)

-2 > z < 2

30 (60.0)

2 or above

1 (2.0)

Weight z score (n = 55)
-2 or below

26 (47.3)

-2 > z < 2

29 (52.7)

2 or above

0 (0.0)

BMI z score (n = 50)
-2 or below

8 (16.0)

-2 > z < 2

42 (84.0)

2 or above

0 (0.0)

In Table 2, the average baseline laboratory characteristics are reported for all
participants at baseline. As expected, the biomarkers for CD4+ T-lymphocytes were low
(average absolute CD4 count of 474, CD4 cell percentage of 13.0). These biomarkers are
currently used by the clinic physicians at KBTH for the timing of ART initiation based
on WHO criteria. The HIV RNA viral load at baseline was found to be over 250,000
copies/ml, indicating robust active infection with high levels of viral replication. On
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average, the study participants were anemic, having a mean hemoglobin count of 8.9 g/dl,
which meets criteria for anemia in any age category.

Table 2. Baseline Laboratory Characteristics (n = 63)
Characteristic
Absolute CD4 cell count (cells/µl)

474 (434)

CD4 cell percentage

13.0 (8.7)

Viral load (copies/ml)

a

Mean (S.D.)

251323 (770457)

Hemoglobin (g/dl)

8.9 (2.5)

WBCa (10^3/µl)

7.3 (4.0)

TLCb (10^3/µl)

3.8 (3.0)

WBC = White Blood Cell count; b TLC = Total Lymphocyte Count
Further details on the baseline laboratory characteristics are displayed in Tables 3

through 5. Table 3 shows the differences in absolute CD4 cell count based on gender,
age, WHO stage and TB diagnosis at or before ART initiation. There was a significant
and expected difference in absolute CD4 count with age (p<0.05). As stated in the
introduction, there is a documented physiological decline in the absolute number of
CD4+ T-lymphocytes as the immune system matures and this number stabilizes after the
age of 5 or 6 years. Therefore, we expected to see a significantly lower absolute CD4
count in the age group 5 years and older. There was also a significant and expected
correlation between a lower absolute CD4 cell count and more advanced WHO stage at
ART initiation (p<0.05). This correlation was expected because a lower absolute CD4
cell count indicates greater immune suppression, making the individual more susceptible
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to opportunistic infections. The WHO stage is a measure of clinical severity based on
clinical findings and opportunistic infections, with more advanced stages associated with
more opportunistic infections. Therefore, it would be expected that individuals with
greater immune suppression due to HIV disease, based on absolute CD4 cell counts,
would have greater disease severity, based on more advanced WHO staging, at the time
of ART initiation. There were no significant differences in absolute CD4 cell count
based on gender or based on past or present TB infection.

Table 3. Baseline Laboratory Characteristics –
Absolute CD4 cell count (n = 63)
Absolute CD4+ T-lymphocyte count (cells/µl)
Characteristic

n

Mean

SD

p value

Female

26

434.5

365.5

0.270

Male

37

555.4

461.0

0 – 2 years

7

712.4

431.2

2 – 5 years

18

689.1

539.3

≥ 5 years

38

380.4

314.3

I

4

877.3

629.7

II

13

498.5

244.5

Gender

Age at ART initiation
0.013

WHO stage at ART initiation
(n = 58)
0.040
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III

23

525.2

409.3

IV

18

320.1

281.1

Yes

24

585.0

501.7

No

38

467.9

367.2

Previous TB infection (n = 62)
0.293

The differences in CD4 cell percentage are shown in Table 4. There were no
significant statistical differences in mean CD4 cell percentage based on gender, age,
WHO stage at baseline, or past or present TB diagnosis. However, there was an observed
difference based on gender with females having a lower CD4 cell percentage at baseline,
but this difference did not reach statistical significance (p=0.057).

Table 4. Baseline Laboratory Characteristics –
CD4 cell percentage (n = 63)
CD4+ T-lymphocyte cell percentage
Characteristic

n

Mean

SD

p value

Female

26

11.6

8.1

0.057

Male

37

15.8

9.0

0 – 2 years

7

14.9

7.6

2 – 5 years

18

15.5

9.1

≥ 5 years

38

13.2

9.0

Gender

Age at ART initiation
0.461
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WHO stage at ART initiation
(n = 58)
I

4

21.9

5.7

II

13

15.5

6.9

III

23

13.6

9.1

IV

18

11.6

9.0

Yes

24

13.4

8.7

No

38

14.8

8.9

0.161

Previous TB infection (n = 62)
0.563

The differences in HIV RNA viral load (copies/ml) are displayed in Table 5. The
data shows that there was a significantly higher viral load in females at the time of ART
initiation compared in males (p<0.05), which perhaps correlated with the observed trend
towards a lower CD4 cell percentage at baseline for females. There was also a
significantly higher viral load found in patients younger than 2 years compared to the
older groups (p<0.05). No significant differences were found in HIV viral load at
baseline based on either disease severity measured by WHO staging or past or present TB
infection.
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Table 5. Baseline Laboratory Characteristics –
HIV viral load (n = 51)
HIV viral load (copies/ml)
Characteristic

n

Mean

SD

p value

Female

22

926414

2182836

0.037

Male

29

58397

136822

0 – 2 years

4

2360665

4719557

2 – 5 years

13

157925

210430

≥ 5 years

34

311146

892797

I

3

113386

196253

II

12

62805

141282

III

22

343407

821244

IV

14

958991

2624576

Yes

20

344480

891319

No

31

489840

1776312

Gender

Age at ART initiation
0.021

WHO stage at ART initiation
0.446

Previous TB infection

B. Effectiveness of first-line ART regimens

0.736
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The effectiveness of the first-line ART regimens was evaluated using the WHO
criteria for treatment failure, immunological failure based on both absolute CD4 cell
count or CD4 cell percentage, and virological failure based on viral load. As previously
explained, a proportion of our enrolled participants were missing data. Of the 87 enrolled
participants, 24 participants were missing CD4 data either at baseline or follow-up data.
The flow chart indicating our data collection is shown in Figure 5, based on the collection
of CD4 data from enrolled participants. This flow chart also indicates the number of
participants meeting the criteria for immunological failure. The participants who did not
meet these criteria were deemed to be receiving effective treatment. In our study, there
were three participants (4.8%) who met the criteria for immunological failure after at
least 24 weeks of ART, and therefore for 95.2% of our study population the first-line
ART was effective for at least the first 24 weeks.

87 enrolled
participants

24 participants
missing CD4 data

63 participants
with complete CD4
data

60 participants
with effective
treatment at 24+
weeks

3 participants with
immunological
failure at 24+ weeks

Figure 5. CD4 data collection flow chart with immunological failures
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As shown in Figure 6, there were 53 participants with complete data to evaluate
treatment effectiveness based on viral load data. There was an increased number of
participants with missing data as compared to CD4 data due to technical difficulties with
the viral load equipment leading to several samples being collected and stored, but not
analyzed. These samples will continue to be stored and may be analyzed at a later date
for further research studies based on the protocol. Based on the WHO definition of
virological failure, there were nine participants (17.0%) who were determined to be
virological failures.

87 enrolled
participants

34 participants
missing VL data

53 participants
with complete VL
data

44 participants
with effective
treatment at 24+
weeks

9 participants
with virological
failure at 24+
weeks

Figure 6. Viral load (VL) data collection flow chart – Virological failures

As explained in the Methods section, all participants with a viral load greater than
5,000 copies/ml after at least 24 weeks on ART would be seen in clinic for clinical
review, assessment of compliance and counseling regarding medication adherence. At
the subsequent visit, repeat blood samples were collected and laboratory testing was
repeated. The purpose of this review and repeat laboratory testing was to gather further
information to indicate whether HIV resistance or non-compliance was the cause for
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reduced viral suppression. There were twelve participants (22.6%) who had viral load
measurements greater than 5,000 copies/ml after at least 24 weeks of ART. For seven of
these participants, the high viral load measurement was the most recent measurement and
therefore they were deemed virological failures for purposes of this data analysis. Five of
the twelve participants had subsequent laboratory testing. Three of the five participants
(60%) had repeat viral load measurements greater than 5,000 copies/ml. The other two
participants (40%) had subsequent viral load measurements that fell to undetectable
levels following the adherence counseling and monitoring.
The virological response to the first-line ART was dramatic and is depicted in the
graphs of Figures 7 and 8. In Fig. 7, the short-term response to ART based on viral load
is depicted in a spaghetti plot using a log-scale. Each line represents an individual
participant and data points up to 30 weeks following ART initiation. Overall, the viral
loads for our study participants decreased steeply over the short-term period following
ART initiation. The individuals for whom the viral load increased over this period were
identified as virological failures and can be seen in Figure 7. In Fig. 8, the longitudinal
response of viral load over the entire study period (up to 24 months) is depicted as mean
viral loads for all individuals with data points. The mean viral load response dropped
exponentially between ART initiation and the second clinic visit at approximately 6
months follow-up, demonstrating the immediate response of participants to first-line
ART regimens. The mean viral load appeared to stabilize after approximately the 6months follow-up visit and remain low.
Additionally, the proportion of participants with undetectable viral load reflected
a strong response. At the second clinic visit, at approximately 6 months, 50% (n=22) of
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participants had an undetectable viral load, defined as less than 400 copies/ml. This
proportion grew significantly at the third clinic visit, at approximately 12 months
following ART initiation, to 76.7% of participants (n=23) and appeared to stabilize at the
18-month (68.4%, n=13) and 24-month (71.4%, n=5) follow-up visits.

Individual response to ART over first 30 weeks:
Viral load (copies/ml), n = 53

Figure 7. Short-term response to ART based on viral load data (copies/ml) from baseline and up to 30
weeks following ART initiation. Each line represents an individual participant.
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Longitudinal viral load response to ART
500000

Mean HIV viral load (copies/ml)

450000
400000
350000
300000
250000
200000
150000
100000
50000
0
1

2

3
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5

Clinic visit number

Figure 8. Trends in the HIV viral load for study participants over the first 5 visits. The mean HIV viral
load (copies/ml) is plotted for each clinic visit. The table below contains the number of participants
included in the analysis at each clinic visit.

Visit
N

1
(0 months)
51

2
(6 months)
44

3
(12 months)
30

4
(18 months)
19

5
(24 months)
7

The difference in immunological (n = 3) versus virological failures (n = 9) was
expected. Based on previous research, as effectiveness of ART wanes, a rise in the viral
load is observed first, followed, sometimes months later, by a decline in the absolute CD4
cell count and CD4 cell percentage. Analyses were conducted to evaluate the agreement
between immunological failure and virological failure determination. Of the three
immunological failures, two were also determined to be virological failures while one
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participant was found to be an immunological failure but not a virological failure.
Conversely, of the nine virological failures, two participants were also immunological
failures and seven participants were not. These data are reported in Table 6 below. Table
6 shows the agreement between the determinations of failures based on immunological
and virological failure. For this analysis, only participants that had both complete CD4
data and complete viral load data were included. The kappa statistic was calculated to be
0.27 (95% CI: -0.07, 0.61).

Table 6. Agreement between failure criteria (n = 53)
Immunological failure
Virological failure

Failure

No failure

Total

Failure

2

7

9

No failure

1

43

44

Total

3

50

53

Kappa = 0.27 (95% CI: -0.07, 0.61)
The effectiveness of the first-line ART regimens was also demonstrated by the
mortality and toxicity data. In our 63 participants with complete CD4 data, there were no
mortalities (0%) in 24 or more weeks of follow-up. Three participants switched ARV
regimen (4.7%). Two participants switched due to toxicity, both secondary to nevirapine
(generalized rash and unspecified toxicity). One participant switched regimens due to
interaction with anti-TB medications.
Predictor variables for immunological, virological and overall treatment failure
were assessed. Associations between baseline laboratory and demographic
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characteristics with immunological failure are demonstrated in Tables 7 and 8. One
predictor variable identified for immunological failure was baseline absolute CD4 cell
count. A lower absolute CD4 cell count was significantly associated with immunological
failure (p<0.05). However, baseline CD4 cell percentage was not found to be associated
with immunological failure (p=0.242). Routine biomarkers such as hemoglobin,
lymphocyte count and white blood cell count did not predict immunological failure at
baseline.
When stratified by three age groups and gender, there were no significant
differences across the groups. All participants with immunological failure had advanced
(stage III) or severe (stage IV) HIV disease at ART initiation, while 32.2% of participants
with effective treatment started ART with asymptomatic (stage I) or mild (stage II)
disease. These differences did not reach statistical significance (p=0.130). A notable
difference was observed in the different ART regimens. All participants with
immunological failure had an EFV-based regimen, which was the most popular regimen
for all participants (79.4%). However, the difference did not reach statistical significance
(p = 0.66).
Participants whose parents were both deceased were more likely to fail treatment
immunologically than participants with at least one parent alive (p<0.05). Other
variables such as caregiver and the HIV status of parents, did not predict the effectiveness
of ART using CD4 criteria. Furthermore, past or present TB infection did not predict
ART effectiveness.
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Table 7. Effectiveness of first-line ART regimens and associations with baseline
laboratory characteristics for IMMUNOLOGICAL FAILURES, n = 63
Baseline Characteristic

Failed

Effective

Treatment (SD),

Treatment (SD),

n=3

n = 60

7.5 (3.4)

6.4 (3.2)

0.563

45 (5.7)

261 (391)

0.222

30.3 (9.9)

499.9 (435.6)

0.041

7.0 (10.4)

13.3 (8.7)

0.242

8680 (12182)

267867 (794118)

0.761

Mean WBC (10^3/µl)

8.4 (1.5)

7.3 (4.1)

0.210

Mean Hgb (g/dl)

9.5 (0.1)

8.8 (2.6)

0.928

Mean TLC (10^3/µl)

3.7 (2.0)

3.8 (3.2)

0.937

Mean BMI (kg/m2)

13.9 (2.0)

14.8 (1.7)

0.331

Mean age at ART

p value

initiation (years)
Time from HIV diagnosis
to ART initiation (days)
Mean absolute CD4 cell
count (cells/µl)
Mean CD4 cell percentage
Mean viral load
(copies/ml)
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Table 8. Effectiveness of first-line ART regimens and associations with baseline
characteristics for IMMUNOLOGICAL FAILURES, n = 63
Baseline Characteristic

Failed

Effective

Total

Treatment

Treatment

population

n (%)

n (%)

n (%)

0 – 2 years

0 (0)

6 (10)

6 (9.5)

2 – 5 years

1 (33.33)

17 (28.33)

18 (28.6)

≥ 5 years

2 (66.67)

37 (61.67)

39 (61.9)

Female

1 (33.33)

26 (43.33)

27 (42.9)

Male

2 (66.67)

34 (56.67)

36 (57.1)

Stage I

0 (0)

3 (5.36)

3 (5.1)

Stage II

0 (0)

15 (26.79)

15 (25.4)

Stage III

1 (33.33)

23 (41.07)

24 (40.7)

Stage IV

2 (66.67)

15 (26.79)

17 (38.8)

3TC/AZT/EFVa

3 (100)

47 (78.33)

50 (79.4)

3TC/AZT/NVPb

0 (0)

11 (18.33)

11 (17.4)

Other

0 (0)

2 (3.34)

2 (3.2)

1 (33.33)

39 (65)

40 (63.5)

p value

Age at ART initiation (years)

0.81

Gender
1.00

WHO staging (n = 59)
0.13

ART regimen
0.66

Caregiver
Mother / Father

0.55
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Other

2 (66.67)

21 (35)

23 (36.5)

2 (66.67)

4 (6.67)

6 (9.5)

Known one alive

0 (0)

21 (35.0)

21 (33.33)

Known both alive

1 (33.33)

35 (58.33)

36 (57.1)

Both parents unknown

1 (33.33)

15 (25.0)

16 (25.4)

One parent with HIV

0 (0)

31 (51.67)

31 (51.7)

2 (66.67)

14 (23.33)

16 (25.4)

Yes

2 (66.67)

23 (38.33)

25 (39.7)

No

1 (33.33)

37 (61.67)

38 (60.3)

Parent status
Both died / Unknown

0.03

Parent HIV status

Both parents with HIV

0.41

Previous TB infection
0.56

a

= lamivudine (3TC), zidovudine (AZT), efavirenz (EFV); b = lamivudine (3TC),
zidovudine (AZT), nevirapine (NVP)
The analysis of predictor variables for virological failures, displayed in Tables 9
and 10, showed that the length of time between HIV diagnosis and ART initiation was
significantly associated with treatment effectiveness. Participants with a shorter time
period between diagnosis and treatment were more likely to fail treatment (p<0.05).
However, baseline absolute CD4 cell count and CD4 cell percentage did not predict
treatment effectiveness for those determined to be virological failures. As with
immunological failures, none of the routine biomarkers (hemoglobin, WBC, TLC)
showed any significant association with treatment effectiveness.
Different age groups or gender did not predict virological failure in this study
population. There were virological failures found in all the various ART regimens,
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which differs from the findings for immunological failures, which were found only for
the 3TC/AZT/EFV regimen. The household demographics (parent living status, parent
HIV status and primary caregiver) also did not predict virological failure in this
population. Additionally, past or present TB infection was not associated with
virological failure.
Table 9. Effectiveness of first-line ART regimens and associations with baseline
laboratory characteristics for VIROLOGICAL FAILURES, n = 53
Baseline Characteristic

Failed

Effective

Treatment (SD),

Treatment (SD),

n=9

n = 44

7.1 (3.9)

6.3 (3.1)

0.452

68.5 (81.0)

295.5 (430.8)

0.037

344.9 (428.0)

508.6 (463.1)

0.309

11.9 (9.2)

12.6 (8.9)

0.810

9261 (22277)

300976 (838818)

0.188

Mean WBC (10^3/µl)

9.5 (7.1)

7.0 (3.3)

0.739

Mean Hgb (g/dl)

9.5 (0.4)

9.0 (2.7)

0.965

Mean TLC (10^3/µl)

4.9 (6.1)

3.7 (2.1)

0.790

Mean BMI (kg/m2)

14.5 (1.7)

14.8 (1.8)

0.676

Mean age at ART

p value

initiation (years)
Time from HIV diagnosis
to ART initiation (days)
Mean absolute CD4 cell
count (cells/µl)
Mean CD4 cell percentage
Mean viral load
(copies/ml)

!60!

Table 10. Effectiveness of first-line ART regimens and associations with baseline
characteristics for VIROLOGICAL FAILURES, n = 53
Baseline Characteristic

Failed

Effective

Total

Treatment

Treatment

population

n (%)

n (%)

n (%)

0 – 2 years

2 (22.22)

3 (6.82)

5 (9.4)

2 – 5 years

1 (11.11)

14 (31.82)

15 (28.3)

≥ 5 years

6 (66.67)

27 (61.36)

33 (66.7)

Female

2 (22.22)

19 (43.18)

21 (43.20)

Male

7 (77.78)

25 (56.82)

32 (56.80)

Stage I

0 (0)

3 (7.32)

3 (6.0)

Stage II

3 (33.33)

11 (26.83)

14 (28.0)

Stage III

2 (22.22)

17 (41.46)

19 (38.0)

Stage IV

4 (44.44)

10 (24.390

14 (28.0)

3TC/AZT/EFVa

6 (66.67)

36 (81.82)

42 (79.20)

3TC/AZT/NVPb

2 (22.22)

7 (15.89)

9 (16.90)

Other

1 (11.11)

1 (2.27)

2 (3.80)

p value

Age at ART initiation (years)

0.23

Gender
0.29

WHO staging (n = 50)
0.39

ART regimen

Caregiver

0.38
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Mother / Father

5 (55.56)

29 (65.91)

34 (64.2)

Other

4 (44.44)

15 (34.09)

19 (35.9)

Both died / Unknown

3 (33.33)

3 (6.82)

6 (11.3)

Known one alive

2 (22.22)

16 (36.36)

18 (36.4)

Known both alive

4 (44.44)

25 (56.82)

29 (54.7)

Both parents unknown

1 (11.11)

11 (25.0)

12 (22.6)

One parent with HIV

4 (44.44)

21 (47.73)

25 (47.2)

Both parents with HIV

4 (44.44)

12 (27.27)

16 (30.2)

Yes

2 (22.22)

17 (38.64)

19 (35.8)

No

7 (77.78)

27 (61.36)

34 (64.2)

0.7

Parent status
0.12

Parent HIV status
0.24

Previous TB infection
0.46

a

= lamivudine (3TC), zidovudine (AZT), efavirenz (EFV); b = lamivudine (3TC),
zidovudine (AZT), nevirapine (NVP)
Predictor variables were analyzed for all participants determined to be failures
based on either immunological or virological criteria (all failures) and results are depicted
in Tables 11 and 12. There was one additional participant included in these analyses (n =
64) because that participant had incomplete CD4 data but complete viral load data. For
all participants that failed treatment, a shorter interval between HIV diagnosis and ART
initiation was found to be significantly associated with treatment failure (failure = 294.1
days, SD=493.6; effective = 332.9 days, SD=523.7, p = 0.014). Additionally, having
both parents with HIV was found to be significantly associated with higher rates of
treatment failure compared to participants with one parent with HIV or both parents with
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unknown HIV status (p = 0.05 across groups). All other baseline characteristics,
including all laboratory-based details, age, gender, WHO staging and previous TB
infection, were not significantly associated with treatment failure. Different ART
regimens were not significantly associated with overall treatment failures.

Table 11. Effectiveness of first-line ART regimens and associations with baseline
laboratory characteristics for ALL FAILURES, n = 64
Baseline Characteristic

Failed

Effective

Treatment (SD),

Treatment (SD),

n = 10

n = 54

6.4 (3.1)

6.4 (3.1)

0.69

294.1 (493.6)

332.9 (523.7)

0.014

473.7 (434.1)

504.1 (434.4)

0.13

13.0 (8.7)

13.4 (8.6)

0.31

251323 (770457)

308299 (848813)

0.31

Mean WBC (10^3/µl)

7.3 (4.0)

6.8 (3.1)

0.29

Mean Hgb (g/dl)

8.9 (2.5)

8.8 (2.8)

0.85

Mean TLC (10^3/µl)

3.8 (3.0)

3.5 (2.0)

0.72

Mean BMI (kg/m2)

14.8 (1.7)

14.8 (1.8)

0.66

Mean age at ART

p value

initiation (years)
Time from HIV diagnosis
to ART initiation (days)
Mean absolute CD4 cell
count (cells/µl)
Mean CD4 cell percentage
Mean viral load
(copies/ml)
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Table 12. Effectiveness of first-line ART regimens and associations with baseline
characteristics for ALL FAILURES, n = 64
Baseline Characteristic

Failed

Effective

Total

Treatment

Treatment

population

n (%)

n (%)

n (%)

0 – 2 years

2 (20.0)

4 (7.41)

6 (9.4)

2 – 5 years

2 (20.0)

16 (29.63)

18 (28.1)

≥ 5 years

6 (60.0)

34 (62.96)

40 (62.5)

Female

2 (20.0)

25 (46.3)

27 (42.2)

Male

8 (80.0)

29 (53.7)

37 (57.8)

Stage I

0 (0)

3 (5.66)

3 (4.8)

Stage II

3 (30.0)

12 (22.64)

15 (23.8)

Stage III

3 (30.0)

21 (39.62)

24 (38.1)

Stage IV

4 (40.0)

13 (24.53)

17 (27.0)

3TC/AZT/EFVa

7 (70.0)

44 (81.48)

51 (79.69)

3TC/AZT/NVPb

2 (20.0)

9 (16.67)

11 (17.19)

Other

1 (10.0)

1 (1.85)

2 (3.13)

p value

Age at ART initiation (years)

0.73

Gender
0.17

WHO staging (n = 60)
0.69

ART regimen

Caregiver

0.37
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Mother / Father

6 (60.0)

34 (63.0)

40 (62.5)

Other

4 (40.0)

20 (37.0)

24 (37.5)

Both died / Unknown

3 (30.0)

4 (7.41)

7 (10.9)

Known one alive

2 (20.0)

19 (35.19)

21 (32.8)

Known both alive

5 (50.0)

31 (57.41)

36 (56.3)

Both parents unknown

1 (10.0)

16 (29.63)

17 (26.6)

One parent with HIV

4 (40.0)

27 (50.0)

31 (48.4)

Both parents with HIV

5 (50.0)

11 (20.37)

16 (25.0)

Yes

3 (30.0)

22 (40.74)

25 (39.1)

No

7 (70.0)

32 (59.26)

39 (60.9)

1.00

Parent status
0.20

Parent HIV status
0.05

Previous TB infection
0.73

a

= lamivudine (3TC), zidovudine (AZT), efavirenz (EFV); b = lamivudine (3TC),
zidovudine (AZT), nevirapine (NVP)
C. Use of absolute CD4 cell count

Analyses were conducted to evaluate both the short-term and long-term response
to ART initiation based on absolute CD4 cell count and CD4 cell percentage. To analyze
the short-term response to ART, spaghetti plots were constructed and are depicted below
in Figures 9 and 10. In both figures, each line represents an individual participant. The
data points included in these plots were baseline measurements and data points up to 30
weeks following ART initiation. The overall trajectories for absolute CD4 cell count
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(Fig. 9) and for CD4 cell percentage (Fig. 10) in the short-term period appeared to be
similar in slope and trend. The graphs illustrate a strong immunological response to firstline ART regimens. Individual declines in absolute CD4 count and CD4 cell percentage
were observed and represent the immunological failures.

Individual response to ART over first 30 weeks:
Absolute CD4 cell count (cells/µl), n = 63

Figure 9. Short-term response to ART based on absolute CD4 cell count. Each line represents an
individual participant.
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Individual response to ART over first 30 weeks:
CD4 cell percentage, n = 63

Figure 10. Short-term response to ART based on CD4 cell percentage. Each line represents an
individual participant.

The longitudinal trends and trajectories of both absolute CD4 cell count and CD4
cell percentage were calculated, depicted in Table 13 and in graph form in Figures 11, 12
and 13. These trends were produced and analyzed based on mean absolute CD4 cell
count and CD4 cell percentage at 6-month intervals following ART initiation. In our
study, we followed participants as long as 24 months after ART initiation. However, the
number of participants included in this trend analysis fell significantly after 12 months of
follow-up.
The trends and trajectories of absolute CD4 cell count and CD4 cell percentage
were observed to be descriptively similar. Both biomarkers increased 70-80% at six
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months, doubled by 12 to 18 months after ART initiation and subsequently rose at a
slower rate. Both absolute CD4 cell count and CD4 cell percentage appeared to stabilize
similarly and plateau around the 18-month visit.
Table 13. Longitudinal trends in CD4 biomarkers on ART
Clinic visit number

1

2

3

4

5

(0 mos)

(6 mos)

(12 mos)

(18 mos)

(24 mos)

505.5

865.4

901.1

1069.3

1041.4

[425.3]

[525.5]

[558.5]

[747.2]

[269.3]

Mean CD4 cell

14.1

25.4

26.0

27.7

29.1

percentage [SD]

[8.8]

[12.4]

[7.8]

[11.0]

[7.35]

Mean absolute CD4
cell count, cells/µl [SD]

Change from baseline value (%)

CD4 change from baseline
120
100
80
60
40
20
0
6

12

18

24

Time since ART initiation (months)
Absolute CD4 cell count
CD4 cell percentage

Figure 11. Trends in the absolute CD4 cell count and CD4 cell percentage as average percent changes
from the participant’s baseline.
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Longitudinal trends in absolute CD4 cell count on ART
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Figure 12. Trends in the absolute CD4 cell count for study participants over the first 5 visits. The mean
absolute CD4 cell count (cells/µl) is plotted with standard deviation markers. The table below contains
the number of participants included in the analysis at each clinic visit. Study visits and data collection
took place every 4-6 months.

Visit
N

1
(0 months)
64

2
(6 months)
54

3
(12 months)
42

4
(18 months)
21

5
(24 months)
9
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Longitudinal trends in CD4 cell percentage on ART
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Mean CD4 cell percentage
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35
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Figure 13. Trends in the CD4 cell percentage for study participants over the first 5 visits. The mean
CD4 cell percentage is plotted with standard deviation markers. The table below contains the number of
participants included in the analysis at each clinic visit. Study visits and data collection took place every
4-6 months.

Visit
N

1
(0 months)
64

2
(6 months)
53

3
(12 months)
42

4
(18 months)
21

5
(24 months)
9
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5. DISCUSSION

A. Effectiveness of first-line ART regimens

The data from this study strongly demonstrate the effectiveness of the first-line
regimen used at KBTH for HIV-infected children. For 83% of the study participants, the
first-line ART regimen was effective. There were no deaths among the children with 24
weeks or more of follow-up. This level of mortality is comparable to previous studies.
For example, in a large West Africa cohort, there was a 92% survival reported at 12
months16. In Cote d’Ivoire, there was a reported survival rate of 92% at 6 months
following ART initiation12. Our study results are limited in number but the high survival
rate strongly supports the effectiveness of the available first-line regimens.
Furthermore, the study data support the high tolerance of the first-line ART
regimen in our population based on the low levels of toxicity, regimen switching and
sustained viral load and CD4 response. There was a 4.7% rate of regimen switching and
only two of the study participants switched because of drug toxicity (3.2%). These rates
of regimen switching and toxicity are comparable to previous studies in the region and in
other resource-limited settings globally. In Kenya, 10% of a pediatric cohort receiving
first-line ART switched regimens due to drug toxicity14 and a smaller percentage, 3.8%,
was reported in a larger study conducted in multiple treatment centers in Africa and
Asia17. The trajectories of viral load, absolute CD4 cell counts and CD4 cell percentages
also support the durability of the first-line regimen in our population and follow-up
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period. At 24 months of follow-up, 71% of our participants had complete viral
suppression (<400 copies/ml), which was increased from the rate of 50% at six months.
ART is life-long therapy and therefore our period of follow-up can only report
preliminary evidence of durability, but the study findings are encouraging.
Both absolute CD4 cell counts and CD4 cell percentages showed a sustained
response through 24 months of follow-up for all ages and genders. Additionally, the
CD4+ T-lymphocyte cell response in our study population reproduced previously
reported data from different participants within the same clinical setting. Renner et al.
reported a doubling of absolute CD4 counts at six months for children at KBTH, a result
that is similar to our data22. The replication of these previously published data validates
the effectiveness of first-line regimens reported and described in this study.
The findings of this study supporting the effectiveness of first-line ART regimens
in Accra, Ghana have important public health implications. These data show that the
currently available regimens, most popularly a regimen of 3TC, AZT and EFV, are
effective in a non-type B HIV genotype, and strongly support the scale-up and roll out of
these current regimens to the broader pediatric HIV community in the region. Based on
the low failure rates, it appears that circulating HIV strains and genotypes among HIVinfected children in Ghana are susceptible to current and available ART. Therefore, the
increased production of low-cost formulations of the current regimen should be pursued.
3TC, AZT and EFV are all approved by the FDA, with some restrictions, for generic
production.
The analysis of the first-line ART effectiveness also identified important
predictors of treatment failure. The most consistent predictor of treatment failure was the
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time interval between HIV diagnosis and ART initiation. The data show a significant
association between shorter intervals from HIV diagnosis to ART initiation and overall
treatment failure (p<0.05). The same association and direction were similarly reported
for virological failure (p<0.05). For the immunological failure data, a shorter mean
interval between HIV diagnosis and ART initiation was observed as well but did not
reach statistical significance. The participants with immunological failure had a shorter
period between diagnosis and treatment, 45 days on average (SD=5.7), compared to an
average period of 261 days (SD=391) for participants with effective treatment (p=0.222).
Increased failure rates for participants with shorter intervals between HIV diagnosis and
ART initiation may be evidence that participants with acute, severe presentations to care
may be more likely to fail treatment.
Age at ART initiation was not found to be significantly correlated with treatment
effectiveness for the overall study population. However, the observed mean age was
higher for individuals with immunological failure (failure = 7.5 years, SD=3.4; effective
= 6.4 years, SD=3.2, p=0.563), as well as virological failure (failure = 7.1 years, SD=3.9;
effective = 6.3 years, SD=3.1, p=0.452). As the patient population increases and the
number of measurements increase, it will be worthwhile to watch to see if these
associations become significant.
Both of these observed associations, interval between diagnosis and ART
initiation and age at ART initiation, support the need for early HIV diagnosis and
treatment. Similar to previous studies in the Africa context, the mean age at ART
initiation was high (6.4 years [SD=3.1]), further supporting the need to improve methods
of early diagnosis.
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HIV screening for pregnant women is an issue beyond the scope of this study but
given the high percentage of new pediatric HIV cases as a result of mother-to-child
transmission, there may be a need for improved policies regarding HIV testing for
pregnant women in Ghana. Currently, there is an opt-in policy in place by which all
pregnant women are offered, by law, HIV testing and the mother decides whether she
would like to be tested. An opt-out policy may be beneficial in order to identify a greater
proportion of HIV-infected women and exposed infants, who regardless of transmission
suffer increased mortality58. The low percentage of patients in this study who
participated in PMTCT (1.6%) may indicate success of the PMTCT program for those
enrolled. The success of prenatal screening and PMTCT in contrast to the high number
of patients seen at the pediatric HIV clinic at KBTH and at older average ages suggests
that ways to further improve early diagnosis should be considered and prioritized.
A lower baseline absolute CD4 cell count appears to be predictive of at least
immunological failure (p<0.05) and a lower mean baseline absolute CD4 cell count was
observed in participants with virological failures but did not reach statistical significance.
When all treatment failures were analyzed together, this association was not found to be
statistically significant. However, this association may indicate a difference in immune
recovery and response for children starting ART at lower absolute CD4 counts. This
result may indicate that participants in our population that had more severe immune
suppression at the time of ART initiation are less likely to recover CD4 T-lymphocyte
counts and improve on treatment.
One additional predictor variable that was reported to be significant for all
treatment failures was parental HIV status. Participants whose parents were both known
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to be HIV-positive had significantly higher rates of treatment failure (p=0.05). This
association was not significant in the analyses for either immunological or virological
failure. As many as 30% of participants that failed treatment had parents whose HIV
status was unknown, which makes interpretation of this association difficult. However,
the association with HIV-positive parents could indicate that HIV-positive parents may
be struggling with their own health issues, hospitalizations, medication adherence, and
may not be adequate supervisors of their child’s health and adherence, which could
contribute to treatment failure.
This study, through research funding and collaboration with the Virology Lab at
KBTH, introduced the routine use of viral load testing to the Pediatric HIV/AIDS Care
Program. The value of viral load testing was illustrated in the analysis of ART
effectiveness. There were twelve participants found to have a viral load of greater than
5,000 copies/ml after at least 24 weeks of ART. Nine of the twelve participants (75%)
were deemed virological failures based on subsequent viral load testing. Additionally,
most (75%) of the increased viral load measurements were found at the 6-month followup visit. This observation reflected the potential value of viral load testing for
identification of early treatment failures and resistance after six months of ART but
decreased value for routine testing beyond six months.
The repeated use of viral load testing for participants with elevated viral loads
highlighted the value of viral load testing for compliance. Reduced adherence is
probably an underlying cause of failure in patients not initially infected with resistant
virus. In our study, 40% of participants retested after adherence counseling and increased
compliance monitoring had undetectable viral loads, indicating a significant proportion of
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participants with a history concerning for poor compliance. Conversely, the 60% of
participants retested had sustained rises in viral load and raised concerns for viral
resistance. These results show the value of viral load testing even in the absence of
resistance testing, as practiced in this study. The use of viral load testing, where
available, could have value for treatment effectiveness, identification of disease
resistance and non-compliance in resource-limited settings.
The analysis of agreement between immunological failures and virological
failures (kappa = 0.27) shows poor agreement. Based on this data, the classification of
treatment failure using CD4 data does not agree well with the classification of treatment
failure using viral load data. The most likely explanation of the poor agreement is a
delay between viral load response and CD4 response as a patient fails treatment. As
shown in previous studies, virological failure may precede immunological failure by
several months and therefore this poor agreement may be expected40. Despite this
expectation and potential explanation, the poor agreement may indicate the value of
having both CD4 and viral load capabilities when monitoring ART in children. Pediatric
HIV programs in resource-limited settings should strive to access facilities capable of
measuring both CD4 and viral load data to optimize the ability to detect treatment
failures. However, this study is not powered for this analysis and therefore any
interpretation is limited.

B. Use of absolute CD4 cell count
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Based on this study’s preliminary and descriptive analysis of absolute CD4 cell
count and CD4 cell percentage as monitoring tools for ART in HIV-infected children,
there is evidence for the potential use of absolute CD4 cell count as an alternative to CD4
cell percentage in settings with limited resources. The trajectories for absolute CD4
count and CD4 cell percentage are similar over both 6-month and 24-month follow-up
periods after ART initiation with similar slopes and trends. The changes from baseline
for absolute CD4 count and CD4 cell percentage showed paralleled increases at each of
the clinic visits.
There were differences in the use of absolute CD4 cell count and CD4 cell
percentage demonstrated by this study that further support the potential use of absolute
CD4 cell count as an acceptable alternative. Absolute CD4 cell count was found to be
predictive of immunological treatment failures as well as significantly associated with
WHO staging at baseline. CD4 cell percentage was neither a predictor variable for
treatment failure nor associated with disease severity based on WHO staging. These
findings may indicate an added value for absolute CD4 cell count as compared to CD4
cell percentage for both timing of ART initiation and monitoring of disease progression.
For absolute CD4 cell count, there was no demonstrated difference between genders and
an expected difference between age groups was observed.
The preliminary support for the use of absolute CD4 cell count evidenced by the
study data has valuable public health implications due to technological advances in CD4
testing. There is already research supporting the economic incentives of absolute CD4
testing and this study supports clinical incentives for absolute CD4 testing. If point-ofcare absolute CD4 cell count technology were acceptable in the pediatric HIV
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community, the widespread implementation of this technology would have deep impact
on the social and economic costs of monitoring pediatric HIV. Point-of-care technology,
being developed only for absolute CD4 cell count capability, would allow ART
monitoring to be done in a home-based program, which could limit stigma associated
with HIV. In this study, guardians frequently expressed to research assistants their own
feelings of being stigmatized themselves (if HIV-positive) and their concerns for any
stigmatization of their children. These feelings and concerns are reflected by the low
levels of disclosure about HIV diagnosis from guardians to children. Furthermore, it
would reduce the costs associated with monitoring including school absence and
transportation costs, which were significant concerns for participants in this study.
More analysis of the longitudinal CD4 data will be undertaken in future related
research to examine differences in absolute CD4 cell count and CD4 cell percentage
based on treatment effectiveness as well as associations with age, gender and other
baseline variables. Mixed modeling will be used to analyze this longitudinal data. Data
from this same cohort will continue to be collected and this author will be directly
involved in the analysis and dissemination of this research.

C. Limitations

This study is relevant to the care and management of HIV-infected children in a
resource-limited setting but does have limitations that should be considered when
interpreting and applying the data. All the participants were recruited and enrolled from
a single center and therefore caution must be used when generalizing the findings of this
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study to other settings in Ghana. KBTH, being the largest hospital in the country, is not
as limited in resources, manpower or facilities, compared to other medical facilities in
Ghana. Therefore, applying the use of this data to settings in which a similar
complement of care is not available may be limited. Furthermore, this study provided a
small amount of funds to participants both as incentive and to defray the transportation
costs. The patient costs to access care observed in this study may pose barriers to
replicating study results as well as initiatives for universal access. Additionally, this
study enrolled few children less than 5 years old and therefore is limited in ability to
apply findings, particularly in the use of absolute CD4 cell count, to all age groups. This
limitation may be a product of late HIV presentation and diagnosis at KBTH, further
evidenced by the advanced age at ART initiation.

D. Conclusions

The development and advancement of ART have made a remarkable impact on
morbidity and mortality attributable to pediatric HIV across the world. As the scale-up of
available ART regimens progresses in the developing world, evaluation of the
effectiveness of these available regimens is essential to ensure the success and safety of
the scale-up process. Furthermore, low cost ways to monitor ART and disease
progression are vital in conjunction with the scale-up of access to ART. This study
demonstrates that the available ART regimens at Korle Bu Teaching Hospital in Accra,
Ghana are effective, well tolerated and potentially durable for children with
predominantly non-type B HIV infection. Results also show low rates of toxicity and
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little evidence for disease resistance in ART-naïve participants. These results support the
scale-up of universal access to the current ART regimens and encourage the production
of low cost formulations to supply the need. However, study results emphasize the need
for improvements in early HIV diagnosis and ART initiation. A shorter interval between
diagnosis and treatment is a predictor of treatment failure of all types and may indicate
poor outcomes for patients who initially present for care with advanced disease.
Absolute CD4 cell count testing appears to have potential as an alternative to CD4 cell
percentage for monitoring ART. The use of absolute CD4 cell count as a monitoring tool
for HIV-infected children of all ages would allow for utilization of emerging, low-cost,
point-of-care technologies with capability only for absolute CD4 count leading to
potentially significant impact on the social and economic limitations of HIV disease
management in resource-limited settings.
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